PE20231679A1 - Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia - Google Patents

Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia

Info

Publication number
PE20231679A1
PE20231679A1 PE2023001878A PE2023001878A PE20231679A1 PE 20231679 A1 PE20231679 A1 PE 20231679A1 PE 2023001878 A PE2023001878 A PE 2023001878A PE 2023001878 A PE2023001878 A PE 2023001878A PE 20231679 A1 PE20231679 A1 PE 20231679A1
Authority
PE
Peru
Prior art keywords
factor
antibodies
methods
antidrug
xia
Prior art date
Application number
PE2023001878A
Other languages
English (en)
Spanish (es)
Inventor
Debra A Freedholm
Daniel M Bloomfield
Royston J Glasspool
Jonathan E Freeman
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of PE20231679A1 publication Critical patent/PE20231679A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PE2023001878A 2020-12-18 2021-12-17 Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia PE20231679A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (1)

Publication Number Publication Date
PE20231679A1 true PE20231679A1 (es) 2023-10-19

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001878A PE20231679A1 (es) 2020-12-18 2021-12-17 Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia

Country Status (19)

Country Link
US (1) US20240077497A1 (https=)
EP (1) EP4264278A4 (https=)
JP (1) JP2023554347A (https=)
KR (1) KR20230121120A (https=)
CN (1) CN116601491A (https=)
AR (1) AR124434A1 (https=)
AU (1) AU2021401421A1 (https=)
CA (1) CA3199482A1 (https=)
CL (1) CL2023001709A1 (https=)
CO (1) CO2023008150A2 (https=)
CR (1) CR20230313A (https=)
CU (1) CU20230031A7 (https=)
EC (1) ECSP23053645A (https=)
IL (1) IL302904A (https=)
JO (1) JOP20230137A1 (https=)
MX (1) MX2023007281A (https=)
PE (1) PE20231679A1 (https=)
TW (1) TW202242414A (https=)
WO (1) WO2022133263A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523802A (ja) * 2022-07-13 2025-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分析物を検出するための弱酸性免疫アッセイ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
MX2020004921A (es) * 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
WO2020231992A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Also Published As

Publication number Publication date
JOP20230137A1 (ar) 2023-06-14
ECSP23053645A (es) 2023-08-31
CL2023001709A1 (es) 2023-11-17
CU20230031A7 (es) 2024-02-07
WO2022133263A1 (en) 2022-06-23
TW202242414A (zh) 2022-11-01
CR20230313A (es) 2023-08-18
AU2021401421A1 (en) 2023-06-22
US20240077497A1 (en) 2024-03-07
IL302904A (en) 2023-07-01
EP4264278A4 (en) 2024-11-27
AR124434A1 (es) 2023-03-29
AU2021401421A9 (en) 2024-10-24
EP4264278A1 (en) 2023-10-25
CA3199482A1 (en) 2022-06-23
JP2023554347A (ja) 2023-12-27
KR20230121120A (ko) 2023-08-17
CN116601491A (zh) 2023-08-15
MX2023007281A (es) 2023-09-04
CO2023008150A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
Monneret et al. How clinical flow cytometry rebooted sepsis immunology
Beaumatin et al. mTORC1 activation requires DRAM-1 by facilitating lysosomal amino acid efflux
MX2023002326A (es) Firma de localizacion celular e inmunoterapia.
Taylor et al. mTOR overcomes multiple metabolic restrictions to enable HIV-1 reverse transcription and intracellular transport
RU2011141499A (ru) Способ определения пола птиц
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
MX2025009080A (es) Analizador de concentracion en el punto de atencion
de Armas et al. Reevaluation of immune activation in the era of cART and an aging HIV-infected population
PE20231679A1 (es) Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
Allanore et al. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?
MX2024008320A (es) Biomarcadores transcripcionales para la respuesta a activadores inmunitarios innatos
CL2011001944A1 (es) Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).
BR112012031255A2 (pt) dispositivo de detecção, aparelho de diálise tendo um dispositivo de detecção, método e uso do método para detecção quantitativa das moléculas predeterminadas
CY1124409T1 (el) Μεθοδος μη επεμβατικης προγεννητικης ανιχνευσης της ανευπλοειδιας του εμβρυικου χρωμοσωματος απο το μητρικο αιμα με βαση τη μεθοδο του βayes
WO2022020733A3 (en) System and methods for detection of pathogenic viruses
Maia-Leite et al. Aortic stiffness aging is influenced by past profound immunodeficiency in HIV-infected individuals: results from the EVAS-HIV (EValuation of Aortic Stiffness in HIV-infected individuals)
WO2020252084A8 (en) Methods and compositions for high sensitivity detection of biothreat pathogens
Kulkarni et al. L-Phenylalanine is a metabolic checkpoint of human Th2 cells
MX2020002450A (es) Dispositivo de analisis y metodo de analisis.
Al-Heety et al. Association of circulating MicroRNA-142-3p with Graves Disease
WO2024015927A3 (en) Analyte detection using aptamers
RU2680885C2 (ru) Биологическое количественное определение пептидогликанов
Zhan et al. Exhausted KLRG1hi CD8+ T and pathogenic GZMA+ Th17 cells are associated with the mild Mycoplasma pneumoniae pneumonia in children
Wang et al. Detection of phosphatidylserine in the plasma membrane of single apoptotic cells using electrochemiluminescence